RESILIENCE helps you survive cancer with a strong heart

European Heart Journal: Study reveals how high blood pressure increases susceptibility to heart damage caused by a key cancer treatment

Anthracyclines are among the most widely used chemotherapy drugs and have been a mainstay of cancer treatment for more than 30 years. Their extraordinary efficacy against numerous solid and hematologic tumors means that they remain first-line drugs today, administered alone or in combination with other therapies. Anthracyclines continue to be the cornerstone of treatment for […]

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions